BACKGROUND:Unopposed estrogen has a central role in development of endometrial benign, premalignant and malignant lesions. The aim of this study was to evaluate the anti-estrogenic effect of metformin on endometrial histology in comparison with progesterone. MATERIALS AND METHODS: A total of 43 patients who were referred to our center for abnormal uterine bleeding and had a histologic diagnosis were disordered proliferative endometrium or simple endometrial hyperplasia were included and randomly distributed in two groups treated with metformin (500mg Bid) or megestrol (40mg daily), respectively, for three months. After this period the patients were evaluated by another endometrial biopsy to assess the impact of the two drugs in restoring normal endometrial histology. RESULTS: Our findings revealed that metformin could induce endometrial atrophy in 21 out of 22 patients (95.5%) while this positive response was achieved in only 13 out of 21 patients (61.9%) in the megstrol group. In addition two low grade endometrial carcinomas in the metformin group responded very well. CONCLUSIONS: We conclude that metformin could be used as an effective antiestrogenic agent in control of abnormal endometrial proliferative disorders.
RCT Entities:
BACKGROUND: Unopposed estrogen has a central role in development of endometrial benign, premalignant and malignant lesions. The aim of this study was to evaluate the anti-estrogenic effect of metformin on endometrial histology in comparison with progesterone. MATERIALS AND METHODS: A total of 43 patients who were referred to our center for abnormal uterine bleeding and had a histologic diagnosis were disordered proliferative endometrium or simple endometrial hyperplasia were included and randomly distributed in two groups treated with metformin (500mg Bid) or megestrol (40mg daily), respectively, for three months. After this period the patients were evaluated by another endometrial biopsy to assess the impact of the two drugs in restoring normal endometrial histology. RESULTS: Our findings revealed that metformin could induce endometrial atrophy in 21 out of 22 patients (95.5%) while this positive response was achieved in only 13 out of 21 patients (61.9%) in the megstrol group. In addition two low grade endometrial carcinomas in the metformin group responded very well. CONCLUSIONS: We conclude that metformin could be used as an effective antiestrogenic agent in control of abnormal endometrial proliferative disorders.
Authors: Amanda de Barros Machado; Vania Dos Reis; Sebastian Weber; Julia Jauckus; Ilma Simoni Brum; Helena von Eye Corleta; Thomas Strowitzki; Edison Capp; Ariane Germeyer Journal: Oncol Lett Date: 2016-08-23 Impact factor: 2.967
Authors: Naomi S Clement; Thomas R W Oliver; Hunain Shiwani; Juliane R F Saner; Caroline A Mulvaney; William Atiomo Journal: BMJ Open Date: 2016-08-16 Impact factor: 2.692
Authors: Teresa Y Lee; Ubaldo E Martinez-Outschoorn; Russell J Schilder; Christine H Kim; Scott D Richard; Norman G Rosenblum; Jennifer M Johnson Journal: Front Oncol Date: 2018-08-28 Impact factor: 6.244